Guillermo Villacampa

Palbociclib, Trastuzumab, and Endocrine Therapy in Pretreated HER2-Positive and PAM50 Luminal Gevorderd Breast Cancer...

A gerandomiseerde study of 2 risk assessment models for individualized breast cancer risk estimation.

HER2DX and survival outcomes in early-stage HER2-positive breast cancer: an individual patient-level meta-analyse.

Immunotherapy and PARP inhibitors as eerstelijns treatment in endometrial cancer: A systematic review and network met...

RAD51 Testing in Patients with Early HER2-Negative Breast Cancer and Homologous Recombination Deficiency: A Post Hoc ...

Adjuvant T-DM1 versus paclitaxel-trastuzumab bij stadium I HER2-positief: ATEMPT vijfjaars

Neoadjuvante checkpointremmers plus chemo bij vroeg mammacarcinoom: meta-analyse

HER2DX genomische test bij HER2-positief mammacarcinoom: APHINITY analyse

Atezolizumab plus bevacizumab plus chemo bij gemetastaseerd/recidief cervixcarcinoom: BEATcc fase III

Neoadjuvante therapie bij HER2-positief mammacarcinoom: NMA van schema's

Checkpointremmers bij thymustumoren: retrospectieve studie

Preoperatieve ribociclib-letrozol versus chemotherapie: QoL FELINE analyse